Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B7-H3 CAR gamma-delta T cells
- Development stage
- Unknown
- Lead developer
- Senlang Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
B7-H3 CAR gamma-delta T cells are an investigational cell-based immunotherapy consisting of gamma-delta (γδ) T cells engineered to express a chimeric antigen receptor (CAR) targeting B7-H3 (CD276). B7-H3 is an immunoregulatory protein belonging to the B7 family that is highly expressed across various solid tumors and hematologic malignancies, including acute myeloid leukemia (AML), pediatric cancers, and brain tumors, while maintaining limited expression in healthy tissues. Gamma-delta T cells, including the Vδ1 and Vγ9Vδ2 subsets, offer unique advantages for allogeneic "off-the-shelf" therapy due to their MHC-independent antigen recognition and inherent anti-tumor cytotoxicity, which minimizes the risk of graft-versus-host disease (GvHD). The therapy is being developed by several entities, including Hebei Senlang Biotechnology (under the code QH104) and Miltenyi Biotec, for the treatment of AML, CNS malignancies, and various B7-H3-positive solid tumors.
- Other names
- B7-H3-targeted CAR-γδT cellsCD276 CAR-gamma-delta T cellsCD-276 CAR-gamma-delta T cellsCD 276 CAR-gamma-delta T cellsB7H3 CAR-γδ T cells
02
Targets
B7-H3
Beyond the preview
Go deeper on B7-H3 CAR gamma-delta T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B7-H3 CAR gamma-delta T cells.